TPST-4903

TPST-4903 (originally designated SL4903) is an investigational, in vivo chimeric antigen receptor T-cell (CAR-T) therapy being developed for the treatment of relapsed or refractory multiple myeloma (rrMM). Originally developed by Hebei Senlang Biotechnology and licensed globally (excluding China) by Tempest Therapeutics, TPST-4903 utilizes a CD7-targeted lentiviral vector platform to deliver CAR constructs directly into endogenous CD7-positive T cells and natural killer (NK) cells inside the patient's body, eliminating the need for ex vivo cell manufacturing. The therapy is designed to dual-target B-cell maturation antigen (BCMA) and G-protein coupled receptor class C group 5 member D (GPRC5D) on malignant plasma cells, aiming to prevent tumor escape and improve efficacy. It is currently being evaluated in the Phase 1 DELIVER-1 dose-escalation study.